Abstract
Background and Aims : Dyslipidemia contributes to the pronounced interconnection between chronic kidney disease (CKD) and cardiovascular disease (CVD). Discovery of the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) led to the development of PCSK9 inhibitors that effectively lower LDL-cholesterol concentrations. Few studies with contradicting results have investigated the association between PCSK9 serum concentrations and cardiovascular outcomes in CKD patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
